Negative copeptin and troponin tests may be used to rule out an acute myocardial infarction…. 

Bariatric surgery is not the only effective treatment regimen in severely obese children…. 

Excessive coffee consumption associated with an increased risk of death….

Over the past few months we have brought you the latest information on SGLT2 Inhibitors, examining this new class of drugs from every angle including how they work, prescription insurance coverage, and both clinician and patient experience with this new medication. Jansen, the manufacturer of the only approved SGLT2 Inhibitor, …

As we move closer to the implementation of the Affordable Care Act, there are still many unanswered questions as to how things will work, challenges from all sides of the political spectrum and healthcare industry, and a lot of misinformation floating around as well. This week, in our Homerun Slides, we …

This we begin a terrific series of Homerun Slides for you on the Afforable Care Act. This first set will cover the Primary Drivers of Healthcare Reform, and then give a brief overview of the goals of the ACA….

Barbara J. Anderson, PhD, CDE and Abigail K. Mansfield Marcaccio, PhD This week’s excerpt answers the following questions:  How do you screen patients for psychological issues at diagnosis of diabetes? When can you use the terms "a touch of sugar" and "borderline diabetes"? How important is it to address misconceptions …

U.S. Department of Health & Human Services Free iOS/Android    The Electronic Preventive Services Selector (ePSS) is an application designed and developed by the U.S. Department of Health & Human Services (HHS), Agency for Healthcare Research and Quality (AHRQ), the nation’s leading federal agency for research on health care quality, …

We have seen numerous studies demonstrating the value of resistance exercise for diabetes patients but often we only think of weights and machines and those methods rule out a lot of our patients. This week, Dr. Sheri Colberg brings us a primer on how all our patients can do some …

Sanofi Withdrawing NDA for Lixisenatide  Sanofi announced they are withdrawing their New Drug Application (NDA) for their once-daily GLP-1 lixisenatide from the FDA. The combination of lixisenatide and Lantus® (basal insulin), the investigational LixiLan fixed-ratio product, remains on schedule to enter into phase 3 in the first half of 2014.